Johnson Controls International PLC vs ResMed Inc. — how do they compare? Johnson Controls International PLC trades at $140 (market cap $85.03B), while ResMed Inc. trades at $197.45 (market cap $28.81B). The key difference: Johnson Controls International PLC is far larger — about 3× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.21%). Which is the better fit depends on your goals.
| JCI | RMD | |
|---|---|---|
Market Cap | $85.03B | $28.81B |
Sector | Industrials | Health |
52-Week High | $148.21 | $293.73 |
52-Week Low | $103.24 | $182.82 |
Enterprise Value | $93.86B | $27.99B |
Dividend Yield | 1.15% | 1.21% |
Signals from Pluang's Aura AI — not financial advice
Johnson Controls International (JCI) trades at $141.71, up 0.89% with a bearish technical signal but strong analyst support. Recent earnings beats and a 14.45% net margin highlight operational strength, while valuation metrics like a P/E of 42.62 suggest premium pricing. The company maintains a dividend and benefits from positive news flow, including industry awards and strategic appointments.
Outlook is mixed: bullish fundamentals and analyst consensus target of $158.29 offer upside, but technical weakness and high valuation pose risks. Key drivers include execution in building systems and data center demand, while debt levels and economic sensitivity require monitoring for sustained growth.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →